Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report: Table 1.

Author:

BERNATSKY SASHA,ROSENBERG ALAN M.,OEN KIEM G.,DUFFY CIARAN M.,RAMSEY-GOLDMAN ROSALIND,LABRECQUE JEREMY,ST. PIERRE YVAN,CLARKE ANN E.

Abstract

Objective.To present preliminary data on incidence of malignancy in juvenile idiopathic arthritis (JIA), compared to general population rates.Methods.We examined cancer occurrence within JIA registries at 3 Canadian pediatric rheumatology centers. The subjects in the clinic registries were linked to regional tumor registries to determine the occurrence of invasive cancers over the observation period (spanning 1974–2006). The total number of cancers expected was determined by multiplying the person-years in the cohort by age, sex, and calendar year-specific cancer rates. The standardized incidence ratio (SIR, ratio of cancers observed to expected) was generated, with 95% confidence intervals.Results.The study sample consisted of 1834 patients. The female proportion was 67.6%; average age at entry to cohort was 8.6 years (SD 5.1). The majority were Caucasian. Subjects contributed 22,341 patient-years (average 12.2, SD 7.8). Within this observation period, one invasive cancer occurred, compared to 7.9 expected (SIR 0.12, 95% CI 0.0, 0.70). This was a hematological cancer (Hodgkin’s lymphoma), representing a SIR for hematological malignancies of 0.76 (95% CI 0.02, 4.21).Conclusion.Only one invasive cancer was identified in this large sample of individuals with JIA, observed for an average of 12.2 years each. These data suggest that, at least in the initial years following diagnosis of JIA, the risk of invasive cancers overall is not markedly increased. The results do not rule out the possibility of a baseline increased risk of hematological malignancies.

Publisher

The Journal of Rheumatology

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference12 articles.

1. U.S. Food and Drug Administration . Postmarket drug safety information for patients and providers. Questions and answers. TNF blockers, Aug 25 2009. [Internet. Accessed Dec 1, 2010.] Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm180694.htm

2. Risk of malignancy among patients with rheumatic conditions

3. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

4. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

5. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3